On December 17 at 3:00 PM Eastern, the American Society of Clinical Oncology and the Infectious Diseases Society of America hosted a panel discussion on the use of the COVID-19 vaccines for cancer patients. The panel included experts in infectious diseases and oncology, and discussed available data on vaccine safety and efficacy, use of vaccines in immunocompromised patients, and management of adverse reactions.
Introductions
Moderator
Stephen S. Grubbs, MD, FASCO
Vice President, Clinical Affairs
American Society of Clinical Oncology (ASCO)
Featured Panelists
Joshua A. Hill
MD Assistant Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
Assistant Professor, Division of Allergy and Infectious Diseases, University of Washington
Michael G. Ison, MD, MS, FIDSA, FAST
Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Director, Center for Clinical Research
Northwestern University Clinical and Translational Sciences Institute
Gary H. Lyman, MD, MPH (Biostatistics), FASCO, FACP, FRCP
Professor, Public Health Sciences and Clinical Research Divisions, Fred Hutchinson Cancer Research Center
Senior Lead, Healthcare Quality and Policy, Hutchinson Institute for Cancer Outcomes Research
Professor of Medicine, Public Health and Pharmacy, University of Washington School of Medicine
Executive Officer, SWOG Cancer Research Network
